TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22799481

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 121
Study: 19588075

Group type: EXPERIMENTAL
Intervention: Bleaching with diode laser (Laser White 10, Biolase) with a diode laser (810 nm, 10 W) activation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bleaching without light activation (Opalescence Xtra Boost, Ultradent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bleaching treatment with a plasma arc lamp (Remewhite, Remedent)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bleaching with a light emitting diode (LED) lamp (By White accelerator, Ensodent)
Number of subjects: 40
Study: 17287387

Group type: EXPERIMENTAL
Intervention: Evidence of diabetes
Number of subjects: 197

Group type: COMPARATOR
Intervention: No evidence of diabetes
Number of subjects: 197
Study: 16060742

Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mortality salience with compatibility of career and children made salient
Number of subjects: 0
Study: 12392343

Group type: EXPERIMENTAL
Intervention: Positive static magnetic field (SMF)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Negative static magnetic field (SMF)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (no SMF)
Number of subjects: 75
Study: 10593670

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 134
Study: 7503851

Group type: COMPARATOR
Intervention: Alfentanil 14.5 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketorolac 1.0 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2248839

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 69
Study: 7025778

Group type: EXPERIMENTAL
Intervention: Probucol (N = 88)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (N = 30)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Probucol (N = 61, continued therapy in open trial)
Number of subjects: 118
Study: 30599109

Group type: EXPERIMENTAL
Intervention: Ultrasound of the hands
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DAS 28 VS
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DAS 28 CRP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: SDAI
Number of subjects: 51
Study: 29030584

Group type: EXPERIMENTAL
Intervention: Transitional objects (TOs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Familiar objects (FOs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Unfamiliar objects (UOs)
Number of subjects: 16
Study: 26207520

Group type: EXPERIMENTAL
Intervention: Television advertisement (TVC)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (no advertisement)
Number of subjects: 384
Study: 24813099

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 360

Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 360
Study: 21442459

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (once-yearly intravenous dose)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Alendronate (once-weekly oral dose)
Number of subjects: 600
Study: 19896879

Group type: EXPERIMENTAL
Intervention: Domiciliary nursing interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care from the institution
Number of subjects: 0
Study: 17550361

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Written Feedback (WF)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 348
Study: 14686964

Group type: EXPERIMENTAL
Intervention: 16 mg candesartan cilexetil
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11848327

Group type: EXPERIMENTAL
Intervention: Cyclosporine-A (6 mg/kg body weight in divided doses for six months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Stanozolol (1 mg/kg body weight/day in divided doses)
Number of subjects: 23
Study: 10091204

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Vit D (300 IU/day and 100 IU/day during the fifth year)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRT + Vit D
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 7818958

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 3391874

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Erythromycin stearate (ES)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pelleted erythromycin base (EB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unprotected EA tablets
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Acid-protected tablets
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unprotected tablet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Protected tablet
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 200 mg acid-protected tablets
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 400 mg acid-protected tablets
Number of subjects: 29
Study: 30599425

Group type: EXPERIMENTAL
Intervention: IV dexamethasone (14 mg tapered over 3 days)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target 80–110 mg·dL−1)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Light anesthesia (Bispectral Index target of 55)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Conventional glucose control (target 180–200 mg·dL−1)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Deep anesthesia (Bispectral Index target of 35)
Number of subjects: 326
Study: 26999625

Group type: EXPERIMENTAL
Intervention: Systematic breathing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study: 25936640

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single dose of MPH
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous MPH administration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIRS measurements
Number of subjects: 50
Study: 23714959

Group type: EXPERIMENTAL
Intervention: Rigid intermaxillary fixation (arch bar and intermaxillary fixation for 7 to 12 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Guiding elastic therapy (arch bar and elastics without rigid intermaxillary fixation for 7 to 12 days)
Number of subjects: 61
Study: 21323786

Group type: EXPERIMENTAL
Intervention: Methyl methacrylate (the liquid part of Unifast TRAD) for 180 seconds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rebase II adhesive according to the manufacturer's instructions
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Methyl formate, methyl acetate, and a mixture of methyl formate‐methyl acetate at various concentrations (75:25, 50:50, 25:75% v/v) for 15 seconds
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group II (negative control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group I (positive control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group III (treated with methyl methacrylate)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group IV (treated with Rebase II adhesive)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Groups V to IX (treated with various concentrations of methyl formate and methyl acetate)
Number of subjects: 90
Study: 19188646

Group type: COMPARATOR
Intervention: Nurse-provided asthma education
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Nurse + CHW-provided asthma education and home support
Number of subjects: 309
Study: 17179873

Group type: EXPERIMENTAL
Intervention: Telephone interpersonal counseling (TIP-C)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Self-managed exercise
Number of subjects: 192

Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 192
Study: 15812253

Group type: EXPERIMENTAL
Intervention: OMRON HEM 705 CP upper arm-cuff device with arm in dependent position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OMRON HEM 705 CP upper arm-cuff device with arm in horizontal position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OMRON R6 oscillometric wrist-cuff device
Number of subjects: 0
Study: 12498339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.45 g/kg alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 12
Study: 9744135

Group type: EXPERIMENTAL
Intervention: Therapist/patient race and sex matching
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Therapist/patient gender matching
Number of subjects: 967

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 967
Study: 8576810

Group type: EXPERIMENTAL
Intervention: L-carnitine supplemented lipid emulsion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: LCT lipid emulsion
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: MCT/LCT lipid emulsion
Number of subjects: 49

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 49
Study: 2504377

Group type: EXPERIMENTAL
Intervention: Squeezing a tennis ball as hard as possible for 30 seconds each day for six weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: No exercise (after six months without exercise)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Non-injured arm of women with fractured forearm (n = 13)
Number of subjects: 99
Study: 999987

Group type: EXPERIMENTAL
Intervention: Naltrexone (40-200 mg per day)
Number of subjects: 155
Study: 30531488

Group type: EXPERIMENTAL
Intervention: Nitrate-rich (NR) supplement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrate-poor (NP) supplement
Number of subjects: 10
Study: 28419206

Group type: EXPERIMENTAL
Intervention: Rehabilitation (HIIT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 151
Study: 26014487

Group type: EXPERIMENTAL
Intervention: Psychoeducation and promotion of health behavior (3-session counseling intervention)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 55
Study: 23632723

Group type: EXPERIMENTAL
Intervention: 2 doses of quadrivalent HPV vaccine at 0 and 6 months (n = 259)
Number of subjects: 830

Group type: COMPARATOR
Intervention: 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261 for girls, n = 310 for young women)
Number of subjects: 830
Study: 21196672

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg ephedrine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ephedrine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ephedrine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1.5 μg/kg phenylephrine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 150
Study: 18059067

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) group programme, 4 sessions in addition to routine hospital care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 42
Study: 17156590

Group type: EXPERIMENTAL
Intervention: Information about physical exercise after one cycle of cytotoxic drugs
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (information about physical exercise after two cycles of cytotoxic drugs)
Number of subjects: 89
Study: 12771874

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Potassium
Number of subjects: 41
Study: 10460951

Group type: EXPERIMENTAL
Intervention: Alpha-1-proteinase inhibitor (A1PI) supplementation at 60 mg/kg on days 0, 4, 7, and 14
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8549573

Group type: COMPARATOR
Intervention: Drink A (2 mmol.l‐1 sodium)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Drink B (26 mmol.l‐1 sodium)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Drink C (52 mmol.l‐1 sodium)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Drink D (100 mmol.l‐1 sodium)
Number of subjects: 6
Study: 2196513

Group type: EXPERIMENTAL
Intervention: Single breath maneuver followed by a breath hold
Number of subjects: 21

Group type: COMPARATOR
Intervention: Panting technique followed by a breath hold
Number of subjects: 21
Study: 390987

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31519167

Group type: EXPERIMENTAL
Intervention: Fortified cereal group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Meat group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Local cereal group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 180
Study: 27449714

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes before tourniquet inflation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tranexamic acid (30 mg/kg) infused intravenously 15 minutes after tourniquet inflation
Number of subjects: 180

Group type: COMPARATOR
Intervention: Tranexamic acid (30 mg/kg) infused intravenously on tourniquet deflation
Number of subjects: 180

Group type: COMPARATOR
Intervention: No tranexamic acid administration
Number of subjects: 180
Study: 25167348

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene block
Number of subjects: 110

Group type: COMPARATOR
Intervention: Neurostimulation-guided interscalene block
Number of subjects: 110
Study: 22052584

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Febuxostat 240 mg
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg vs Allopurinol
Number of subjects: 226
Study: 19464413

Group type: EXPERIMENTAL
Intervention: Patients with mixed pulmonary hypertension (MPH)
Number of subjects: 171
Study: 17365917

Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg/day) + Amoxicillin (750 mg/day) + Clarithromycin (400 mg/day) for 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lansoprazole (60 mg/day) + Clarithromycin (400 mg/day) for 7 days
Number of subjects: 31
Study: 15129381

Group type: EXPERIMENTAL
Intervention: Advanced access appointment system
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional access system
Number of subjects: 2
Study: 12029279

Group type: EXPERIMENTAL
Intervention: 3‐cornered flap
Number of subjects: 14

Group type: COMPARATOR
Intervention: Szmyd flap
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both flaps
Number of subjects: 14
Study: 9862244

Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 4 tablets over 48 h
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 4 x 2 tablets over 48 h
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CGP 56697 (artemether 20 mg + benflumetol 120 mg) 3 x 4 tablets over 24 h
Number of subjects: 260
Study: 7623073

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 or 25 Gy delivered in a single fraction
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 36
Study: 2618634

Group type: EXPERIMENTAL
Intervention: One-stage treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-stage treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 35192

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clobazam 30 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dipotassium clorazepate 15 mg
Number of subjects: 44
Study: 31900758

Group type: EXPERIMENTAL
Intervention: Elevated serum CRP levels (per standard deviation increase)
Number of subjects: 418642

Group type: EXPERIMENTAL
Intervention: High CRP levels (> 3 mg/L)
Number of subjects: 418642

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses using different MR models
Number of subjects: 418642

Group type: EXPERIMENTAL
Intervention: Multivariable MR adjusting for other AMD risk factors
Number of subjects: 418642
Study: 31447131

Group type: EXPERIMENTAL
Intervention: Niacin-laropiprant (2000/40 mg/d)
Number of subjects: 25673
Study: 28615356

Group type: EXPERIMENTAL
Intervention: Sulforaphane (provided as concentrated broccoli sprout extract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulforaphane
Number of subjects: 0
Study: 26179616

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement with added micronutrients
Number of subjects: 1815

Group type: COMPARATOR
Intervention: Lipid-based nutrient supplement without added micronutrients
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Reduction in serum CRP from recruitment to week 6
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Change in serum CRP
Number of subjects: 1815
Study: 23354657

Group type: EXPERIMENTAL
Intervention: Topical hemoglobin solution added to standard wound care
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard wound care without hemoglobin
Number of subjects: 72
Study: 21859640

Group type: EXPERIMENTAL
Intervention: Mucosolvin (15 mg/kg per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no respiratory drug)
Number of subjects: 100
Study: 18982311

Group type: EXPERIMENTAL
Intervention: Hamstring tendons (HT) graft
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patellar tendon (PT) graft
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 17885566

Group type: EXPERIMENTAL
Intervention: Fast Track Program
Number of subjects: 891

Group type: COMPARATOR
Intervention: Control
Number of subjects: 891
Study: 16437139

Group type: EXPERIMENTAL
Intervention: Sequential ATRA and chemotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: ATRA treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Detection of mutant subclones
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pre-therapy detection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subsequent ATRA therapy
Number of subjects: 18
Study: 12579384

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. preoperatively followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v. bolus before the end of the operation followed by 8 mg every 8 h for a total of 24 mg in the first 24 h
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo before and after the operation and for the first 24 h
Number of subjects: 66
Study: 10770346

Group type: COMPARATOR
Intervention: ZDV/ddI
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: ZDV/ddI/NVP
Number of subjects: 170
Study: 9020808

Group type: EXPERIMENTAL
Intervention: Probabilistic criterion for response anticipation in the absence of a warning stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli discrimination task
Number of subjects: 0
Study: 1746711

Group type: EXPERIMENTAL
Intervention: pH-stat management (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: alpha-stat management (group II)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control values (normothermia)
Number of subjects: 42
Study: 7174622

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 30941063

Group type: EXPERIMENTAL
Intervention: Quitlink intervention with peer worker support and referral to the Victorian Quitline for an 8-week cognitive behavioral intervention and nicotine replacement therapy (NRT)
Number of subjects: 382

Group type: COMPARATOR
Intervention: No further intervention (control group)
Number of subjects: 382
Study: 28785986

Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel (CP)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Platinum/5-Fluorouracil (PF)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 124
Study: 26112745

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23392737

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21206285

Group type: EXPERIMENTAL
Intervention: High-dosage right unilateral (RUL) ECT
Number of subjects: 184

Group type: COMPARATOR
Intervention: Moderate-dosage bilateral (BL) ECT
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) plus lithium (Li)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) plus lithium (Li)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Continuation treatment with VEN + Li
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Continuation treatment with NT + Li
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Remission status
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 184
Study: 19273782

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy (n = 1509)
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy with upper-tertile HDL-C response (>8 mg/dL)
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy with lower-tertile HDL-C response (<=8 mg/dL)
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Cumulative probability of death at 16 years for bezafibrate with upper-tertile HDL-C response
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Cumulative probability of death at 16 years for bezafibrate with lower-tertile HDL-C response
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Placebo therapy (n = 1517)
Number of subjects: 3026